Share
Paid news dissemination
JOIN OUR FREE TODAY
Join Free
Investorideas.com (www.investorideas.com newswire) a trusted investment platform for retail investors reports breaking
Medical Tech Stock news for
Aethlon Medical, Inc.
(Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing
products to treat cancer and life-threatening viral infections for
which there is no treatment.
Industry commentary: SentimenTrader notes that healthcare has
quietly demonstrated strong defensive qualities, outperforming
the S&P 500 on 85% of the days the broader market posted
losses of 1% or more over the past year. This resilience
underscores the sector’s potential as a reliable performer
during market downturns.
Aethlon Medical, Inc.
(Nasdaq: AEMD) today reported financial results for its fiscal year ended March
31, 2026, and provided an update on recent developments.
Summary – Australian oncology study advances
into Cohort 3 as enrollment continues
Entered the third and final dosing cohort of the Australian oncology
study, expanded the Hemopurifier intellectual property portfolio, and
maintained a focus on managing operating expenses.
Conference Call Today at 4:30 p.m. ET
Key Highlights
- Advanced the Australian oncology study through completion of the first two cohorts and entered the third and final dosing cohort, representing a key clinical milestone toward generating data to inform future development and dosing strategy.
- Recently treated the first participant in Cohort 3 at Royal North Shore Hospital in Australia. The participant completed three Hemopurifier treatments over a one-week period, marking continued enrollment momentum and execution of the study’s final treatment arm.
- Advanced preclinical research evaluating Hemopurifier applications in additional disease areas, including rheumatoid arthritis and chronic kidney disease, supporting the expansion of the platform’s potential addressable market beyond oncology and infectious disease.
- Continued to strengthen the intellectual property portfolio supporting the Hemopurifier platform, including the issuance of patents in the United States and Europe covering potential applications for long COVID and other coronavirus-related conditions, extending patent protection into the 2040s and enhancing long-term platform value.
“Fiscal 2026 was a year of meaningful execution for Aethlon as we
advanced our Australian oncology study through the first two cohorts
and recently initiated Cohort 3.
Advancement into the final cohort represents an important
clinical milestone as we work toward generating data that may help
define the optimal treatment regimen and guide future development
decisions.
We also strengthened the Hemopurifier platform through expansion of
our intellectual property portfolio and advancement of preclinical
research supporting potential applications beyond oncology.
Combined with our continued focus on managing operating expenses,
these achievements position us to pursue multiple value-creating
opportunities across our clinical and research programs.” said James Frakes, Chief Executive Officer and Chief Financial
Officer of Aethlon Medical.
Clinical Update
Clinical Progress in Cancer Trial
Enrollment and treatment of participants in Cohort 2 of the
Australian oncology trial have been completed. An independent Data
Safety Monitoring Board reviewed the data, identified no safety
concerns based on its review of available data, and recommended
advancing to the third and final cohort. Screening is actively
underway at the three investigative sites for this final cohort where
3-6 participants will be treated with 3 Hemopurifier sessions during a
1-week period. The first participant in Cohort 3 of the study has been
enrolled and received three Hemopurifier treatments without any device
deficiencies or immediate complications and is now in the follow-up
period. Successful enrollment and treatment of the first participant in
Cohort 3 maintains the study’s clinical momentum and moves the Company
closer to completing enrollment and generating data from all planned
dosing regimens.
Serial Extracellular Vesicle and T cell measurements on participants
in cohort 2 have been measured by the central lab at the University of
Sydney. Formal statistical analyses comparing the effects of the three
different Hemopurifier dosing regimens on these parameters will be
performed by a CRO at the completion of the trial. This nine-to-18
patient study is designed to evaluate the safety and feasibility of the
Hemopurifier treatments and determine the appropriate dosing in
participants with solid tumors whose disease is stable or progressing
while on a treatment that includes the anti-PD-1 agents, Keytruda(R)
or Opdivo(R).
Other Recent Developments
During fiscal 2026, we strengthened our intellectual property
portfolio through the issuance of patents in both the United States
and Europe covering potential applications of the Hemopurifier for
coronavirus-related conditions, including long COVID and other
post-infection complications. These patents extend protection for
certain applications of the Hemopurifier into the 2040s and further
strengthen the Company’s intellectual property position surrounding the
Hemopurifier.
In addition, we advanced our preclinical extracellular vesicle (EV)
research activities, including studies evaluating removal of EVs in
plasma samples from patients with rheumatoid arthritis and chronic
kidney disease. These efforts support the Company’s ongoing evaluation
of the Hemopurifier’s potential applications across multiple disease
categories and
may create future opportunities to expand the platform into large
markets characterized by significant unmet medical need.
Separately, we continued our evaluation of Hemopurifier compatibility
with a simplified blood treatment system being developed by Stavro
Medical. Initial testing assessing flow rates and transfer of fluid
through the Hemopurifier has been completed, and future studies
evaluating removal of surrogate markers for extracellular vesicles by
the Hemopurifier using the system are under consideration. We believe
this approach could expand potential treatment settings for the
Hemopurifier in the future and
may improve the scalability and accessibility of treatment if
successfully developed and validated.
Subsequent to fiscal year-end, an interview published in IEEE Spectrum
featuring Aethlon’s Chief Medical Officer and a physician involved in
the treatment of an Ebola virus disease patient with the Hemopurifier
during the 2014 outbreak highlighted the Company’s experience with
Ebola treatment efforts. In connection with renewed public health
interest surrounding recent Ebola outbreaks, we also confirmed the
continued availability of our FDA-authorized expanded access
(compassionate use) protocol and shared the protocol as well as past
in vitro and in vivo data with organizations involved in global and
U.S. emerging pathogen preparedness efforts, including the World Health
Organization’s R&D Blueprint expert panel and the National Emerging
Special Pathogen Training and Education Center.
Financial Results for the Fiscal Year Ended March 31, 2026
As of March 31, 2026, the Company had approximately $5.0 million in
cash and cash equivalents, providing resources to support ongoing
clinical and research activities.
Subsequent to fiscal year-end, the Company strengthened its balance
sheet by raising approximately $1.85 million in net proceeds through
its at-the-market program.
Consolidated operating expenses declined 21.9% year-over-year to
approximately $7.3 million, reflecting continued expense discipline and
operational efficiency while advancing the Company’s clinical and
research priorities compared to $9.3 million for the fiscal year ended
March 31, 2025. The decrease was primarily due to $1.1 million
reduction in payroll and related expenses, a $500,000 reduction in
general and administrative expenses and a $400,000 reduction in
professional fees.
Consistent with the reduction in operating expenses, the operating
loss for the fiscal year decreased to approximately $7.3 million for
fiscal 2026 from $9.3 million in the prior fiscal year.
Other income was approximately $142,000 for the fiscal year ended
March 31, 2026, primarily reflecting interest income earned on cash
balances, compared to other expense of approximately $4 million in the
prior fiscal year. The prior-year amount included approximately $4.7
million of non-cash financing-related charges.
Net loss attributable to our common stockholders was $7.2 million for
the fiscal year ended March 31, 2026, compared to net loss of $13.4
million for the fiscal year ended March 31, 2025.
Conference Call
Management will host a conference call today, Wednesday, June 10,
2026, at 4:30 p.m. ET to review the Company’s financial results and
recent corporate developments. Following management’s formal remarks,
there will be a question-and-answer session.
Interested parties can register for the conference call by navigating
to
https://dpregister.com/sreg/10209612/1042263e8ec. Please note that registered participants will receive their dial-in
number upon registration.
Interested parties without internet access or unable to pre-register
may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after
the end of the call through July 10, 2026. The replay can be accessed
via Aethlon Medical’s website or by dialing 1-855-669-9658 (USA or
Canada) or 1-412-317-0088 (international) or Canada toll free at
1-855-669-9658. The replay conference ID number is 7883435.
About the Hemopurifier(R)
The Aethlon Hemopurifier is an investigational medical device designed
to remove enveloped viruses and tumor-derived extracellular vesicles
(EVs) from circulation. It is used extracorporeally with a blood pump
and combines plasma separation, size exclusion, and affinity binding
using a plant lectin resin that targets mannose-rich surfaces found on
EVs and viruses. EVs released by solid tumors are believed to play a
role in metastasis and the resistance to immunotherapies and
chemotherapy. Removal of enveloped viruses and extracellular vesicles
has been demonstrated in both in vitro studies and human subjects.
The Hemopurifier holds a U.S. Food and Drug Administration Breakthrough
Device Designation for:
The treatment of individuals with advanced or metastatic cancer
unresponsive to or intolerant of standard-of-care therapy; and the
treatment of life-threatening viruses not addressed with approved
therapies.
Full news and financials from AEMD
More info on AEMD at Investorideas.com
Get News Alerts on Aethlon Medical
Research biotech stocks at Investorideas.com:
https://www.investorideas.com/Companies/RenewableEnergy/stock_list.asp
Sign up for free stock news alerts at Investorideas.com:
https://www.investorideas.com/Resources/Newsletter.asp
About Investorideas.com – Big Investing Ideas
Investorideas.com
is a trusted platform for retail investors, serving as a hub for
innovative investing ideas for over 25 years. Known for its pioneering
coverage of sectors like mining, cleantech, defense, and water stocks,
the company and its executives have been featured in high-profile
media outlets for its expertise. Investorideas.com is always at the
forefront of investment trends, offering coverage of diverse
industries such as AI, mining, and tech. With a mission to empower
investors, the company provides breaking news, sector-focused
articles, podcasts, and exclusive interviews with leading experts. In
addition, its award-winning branded content, AI-driven short videos,
and podcasts highlight key investing insights and feature prominent
industry leaders.
Investor Ideas digital advertising and guest posts service:
https://www.investorideas.com/Advertise/
Follow us on X @investorideas @stocknewsbites
Follow us on
Facebook
https://www.facebook.com/Investorideas
Follow Investorideas and the Exploring Mining Podcast on YouTube
https://www.youtube.com/c/Investorideas
Investors stay ahead by signing up for free stock news alerts at
Investorideas.com
Join our free Telegram community
https://t.me/+o8DxSAgeNCk2ZGVh
Contact us for more info
Call 800 665 0411
Aethlon Medical, Inc. (Nasdaq: AEMD) is a paid featured medical tech
stock on Investorideas.com.
More disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of
stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and
marketing, content creation and more.
More disclosure: Contact management and IR of each company directly regarding specific
questions.
